Efforts are underway to increase access to cell and gene therapies, with various initiatives aiming to address industry challenges and break down barriers. These efforts include reimagining reimbursement models, democratizing genomic data, and reducing manufacturing costs for gene therapies. Additionally, specific plans are being developed to support patients with certain diseases, such as sickle cell disease, although the scope and details of these plans are not entirely clear.